|
|
| |
| Most Discussed Stocks |
 |
|
|
|
| |
|
Stocks >> Stocks Details |
|
XOMA |
| |
|
|
|
|
|
XOMA |
| |
|
XOMA discovers, develops and manufactures therapeutic antibodies for cancer and immune diseases. XOMA has royalty interests
in RAPTIVA(r) (efalizumab), a monoclonal antibody product
marketed worldwide (by Genentech, Inc. and Merck Serono
S.A.) to treat moderate-to-severe plaque psoriasis, and
LUCENTIS(r) (ranibizumab injection), a monoclonal antibody
product marketed worldwide (by Genentech and Novartis AG)
to treat neovascular (wet) age-related macular degeneration. The firm owns a discovery and development
platform that includes access to seven of the leading commercially
available antibody phage display libraries and XOMA's proprietary
Human Engineering(HE) and Bacterial Cell Expression (BCE) technologies. More than 45 companies have signed BCE licenses.
XOMA's development collaborators include Lexicon genetics, Novartis; Schering-Plough Research Institute and Takeda
Pharmaceutical Company Limited. With a fully integrated
product development infrastructure, XOMA's capabilities
extend from preclinical sciences to product launch.
|
| |
| |
| |
| |
| |
| |
|
| |
|
